Efficacy of Unani formulation in Iron Deficiency Anaemia

Efficacy and Safety of Qurs Damavi in Iron Deficiency Anaemia - A Randomised Controlled Clinical Trial - nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/06/069074

Enrollment

Registered

2024-06-18

Start date

Unknown

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D509- Iron deficiency anemia, unspecified

Interventions

Intervention1: Qurs Damavi: 500mg once daily orally for 60 days in test group Control Intervention1: Qurs Damavi: 500mg Twice a day orally on alternate days for 60 days in the control group.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects with Haemoglobin less than or equal to 11g/dl to greater than or equal to 6g/dl 2. Age from 18-65 years 3. All Genders

Exclusion criteria

Exclusion criteria: 1. Subjects with very severe anaemia haemoglobin less than 6g/dl. 2. Subjects taking medication for iron deficiency anemia, with a history of allergy to herbal medicines. 3. Subjects with uncontrolled hypertension, cardiovascular complications, with hepatic abnormality, or renal diseases. 4. Pregnant and lactating women. 5. Subjects with causes other than iron deficiency anaemia.

Design outcomes

Primary

Measure	Time frame
Improvement in Objective parameters-Hb%,RBC PCV,MCV,MCH,MCHC,RDW,PS, S.FerritinTimepoint: 0th, 30th, 60th day, post follow up 90th day.	—

Secondary

Measure	Time frame
Improvement in Subjective parameters Pallor,Breathlessness and FatigueTimepoint: 0th, 30th, 60th,post follow up 90th day.	—

Countries

India

Contacts

Public ContactDr Rukhsar Chowdhary

National institute of unani medicine, kottegepalya, Magadi main road Bangalore

drmaquamri@gmail.com9341072974

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026